Spelling suggestions: "subject:"hematopoietic step progenitor cell"" "subject:"ematopoietic step progenitor cell""
1 |
In vitro hematopoietic stem/progenitor cell proliferation and labelingXu, Peng Unknown Date
No description available.
|
2 |
In vitro hematopoietic stem/progenitor cell proliferation and labelingXu, Peng 06 1900 (has links)
Hematopoietic stem/progenitor cells (HSPC) play main role in constituting the whole hematopoietic system. Furthermore, since recognized in 1960s, HSPC are utilized to protect patients from severe chemo and radio therapy. As time goes, they are also used to treat hematopoietic disorders such as leukemia. Bone marrow, peripheral blood and umbilical cord blood are now the three sources of HSPC. Umbilical cord blood seems optimal because it is easy to obtain, no risk to graft donor and low probability of infection transmission. However, low number of HSPCs in umbilical cord blood is the main limitation. My research focuses mainly on in-vitro proliferation of HSPCs. In addition, I also worked on labeling HSPC in-vitro for tracking these cells after transplantation. The experimental results indicated that HSPCs are effectively labeled and their proliferation rate is significantly enhanced in-vitro. / N/A
|
3 |
Enabling the Next Generation of Human Induced Pluripotent Stem Cell Derived Hematopoietic Stem Cell-Based TherapiesWong, Casey 23 August 2023 (has links)
Human induced pluripotent stem cells (iPSCs) represent a scalable cell source for the generation of hematopoietic progenitor cells (iHPCs); however, a lack of efficient iHPC expansion in vitro currently limits translational applications. To address this translational bottleneck, we assessed a panel of stem cell agonist cocktails (SCACs), originally developed to enhance cord-blood derived HSPC (CB-HSPC) expansion, on iHPC expansion. Three SCACs and GAS6 (X2A, X2A+GAS6, SM6, or SMA) were supplemented during iHPC differentiation and subsequent expansion using the STEMdiff™ Hematopoietic Kit. This monolayer differentiation strategy yielded a population of CD34⁺CD43⁺ and CD45⁺CD34⁺ iHPC. SCAC supplementation during iHPC differentiation yielded up to 2.5-fold higher frequency of CD34⁺CD43⁺ hematopoietic progenitors and up to 2.9-fold higher frequency of CD45⁺CD34⁺CD45RA⁻CD90⁺ HSC-like cells compared to non-treated controls. Subsequent SCAC supplementation during 2 weeks of expansion culture also significantly increased iHPC expansion (X2A+GAS6: 3.8-fold, X2A: 3.5-fold, SM6: 2.8-fold, SMA: 2.0-fold). The expanded iHPCs retained high levels of CD34⁺CD43⁺ expression but we observed an increase in the expansion of HSC-like cell fraction. The collective expansion observed with the SCACs was 1.5- to 2.8-fold higher than UM171 treatment alone. Furthermore, all SCAC-supplemented iHPCs retained multilineage potency, producing erythroid and granulocyte-macrophage progenitors in CFU assays. However, prolonged expansion, beyond 7 days, reduced multilineage potential, indicating a limited expansion window. Although optimal timing and composition of SCAC supplementation remains to be refined, these results highlight that exploiting the additive and synergistic effects of multiple small molecules represents a promising approach for enhancing iHPC expansion yields and biomanufacturing.
|
Page generated in 0.1272 seconds